NASDAQ:DCTH Delcath Systems (DCTH) Stock Forecast, Price & News $7.96 +0.16 (+2.05%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$7.81▼$7.9950-Day Range$4.67▼$7.9652-Week Range$2.34▼$7.99Volume76,509 shsAverage Volume42,260 shsMarket Capitalization$84.54 millionP/E RatioN/ADividend YieldN/APrice Target$16.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Delcath Systems MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside109.4% Upside$16.67 Price TargetShort InterestBearish4.31% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.21Based on 10 Articles This WeekInsider TradingAcquiring Shares$95,087 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.40) to ($1.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 starsMedical Sector748th out of 1,006 stocksSurgical & Medical Instruments Industry78th out of 104 stocks 3.5 Analyst's Opinion Consensus RatingDelcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.67, Delcath Systems has a forecasted upside of 109.4% from its current price of $7.96.Amount of Analyst CoverageDelcath Systems has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.31% of the outstanding shares of Delcath Systems have been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Delcath Systems has recently increased by 7.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DCTH. Previous Next 1.8 News and Social Media Coverage News SentimentDelcath Systems has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Delcath Systems this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for DCTH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have bought more of their company's stock than they have sold. Specifically, they have bought $95,087.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders16.76% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.66% of the stock of Delcath Systems is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Delcath Systems are expected to grow in the coming year, from ($2.40) to ($1.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Delcath Systems (NASDAQ:DCTH) StockDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Read More Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address DCTH Stock News HeadlinesMay 30, 2023 | americanbankingnews.comDelcath Systems, Inc. (NASDAQ:DCTH) Expected to Post Q2 2023 Earnings of ($0.89) Per ShareMay 28, 2023 | americanbankingnews.comDelcath Systems (NASDAQ:DCTH) Rating Increased to Hold at StockNews.comMay 31, 2023 | Behind the Markets (Ad)Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>May 26, 2023 | americanbankingnews.comAnalysts Offer Predictions for Delcath Systems, Inc.'s Q1 2024 Earnings (NASDAQ:DCTH)May 16, 2023 | americanbankingnews.comDelcath Systems, Inc. (NASDAQ:DCTH) Sees Significant Increase in Short InterestMay 12, 2023 | finanznachrichten.deDelcath Systems, Inc.: Delcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial ResultsMay 12, 2023 | finance.yahoo.comDelcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial ResultsMay 11, 2023 | seekingalpha.comDelcath Systems Q1 2023 Earnings PreviewMay 31, 2023 | Behind the Markets (Ad)Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>May 11, 2023 | americanbankingnews.comDelcath Systems (DCTH) Scheduled to Post Quarterly Earnings on FridayMay 9, 2023 | finance.yahoo.comDelcath Systems to Participate in the Lytham Partners Spring 2023 Investor ConferenceMay 3, 2023 | finance.yahoo.comDelcath Systems to Host First Quarter 2023 ResultsApril 30, 2023 | americanbankingnews.comDelcath Systems, Inc. (NASDAQ:DCTH) Short Interest UpdateApril 23, 2023 | americanbankingnews.comDelcath Systems (NASDAQ:DCTH) Coverage Initiated at StockNews.comApril 7, 2023 | americanbankingnews.comDelcath Systems (NASDAQ:DCTH) Receives New Coverage from Analysts at StockNews.comApril 3, 2023 | finance.yahoo.comDelcath Systems Announces Resumption of Interest-Only Period for Company's Debt FacilityApril 1, 2023 | americanbankingnews.comGerard J. Michel Acquires 19,646 Shares of Delcath Systems, Inc. (NASDAQ:DCTH) StockMarch 30, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Delcath Systems, Inc. Raised by Analyst (NASDAQ:DCTH)March 30, 2023 | americanbankingnews.comDelcath Systems (NASDAQ:DCTH) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPSMarch 30, 2023 | americanbankingnews.comDelcath Systems (NASDAQ:DCTH) Coverage Initiated by Analysts at StockNews.comMarch 29, 2023 | finance.yahoo.comDelcath Systems Announces Closing of Private Placement of up to $85 MillionMarch 29, 2023 | americanbankingnews.comDelcath Systems, Inc. (NASDAQ:DCTH) Expected to Post FY2027 Earnings of $1.07 Per ShareMarch 28, 2023 | americanbankingnews.comHC Wainwright Lowers Delcath Systems (NASDAQ:DCTH) Price Target to $17.00March 28, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Delcath Systems (DCTH)March 27, 2023 | finance.yahoo.comWhy Delcath Systems Shares Are Jumping TodayMarch 27, 2023 | finanznachrichten.deDelcath Systems, Inc.: Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateMarch 25, 2023 | americanbankingnews.comReviewing Delcath Systems (NASDAQ:DCTH) and RenovaCare (OTCMKTS:RCAR)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address DCTH Company Calendar Last Earnings5/22/2023Today5/31/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DCTH CUSIPN/A CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees55Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.67 High Stock Price Forecast$19.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+109.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,510,000.00 Net Margins-1,212.45% Pretax Margin-1,242.19% Return on Equity-1,396.28% Return on Assets-158.81% Debt Debt-to-Equity RatioN/A Current Ratio2.16 Quick Ratio1.99 Sales & Book Value Annual Sales$2.72 million Price / Sales31.04 Cash FlowN/A Price / Cash FlowN/A Book Value($1.23) per share Price / Book-6.46Miscellaneous Outstanding Shares10,620,000Free Float8,841,000Market Cap$84.43 million OptionableNot Optionable Beta0.86 Key ExecutivesMr. Gerard J. Michel MBA (Age 60)MS, CEO & Director Comp: $683.82kMr. John Purpura M.S. (Age 62)Chief Operating Officer Comp: $482.56kDr. Johnny John M.D. (Age 59)Sr. VP Clinical Devel. & Medical Affairs Comp: $383.63kMr. Anthony C. Dias (Age 56)VP of Fin. Mr. David HoffmanGen. Counsel, Corp. Sec. & Chief Compliance OfficerMr. Robin WaggeSr. VP of Rubenstein AssociatesMr. Kevin MuirVP of Commercial OperationsMore ExecutivesKey CompetitorsLyra TherapeuticsNASDAQ:LYRAProSomnusNASDAQ:OSANeuroneticsNASDAQ:STIMAkiliNASDAQ:AKLIMeihua International Medical TechnologiesNASDAQ:MHUAView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCBought 2,851 shares on 5/16/2023Ownership: 0.591%BlackRock Inc.Bought 3,032 shares on 5/12/2023Ownership: 0.157%Renaissance Technologies LLCBought 12,100 shares on 5/12/2023Ownership: 0.114%Tower Research Capital LLC TRC Bought 2,419 shares on 5/9/2023Ownership: 0.044%Advisors Capital Management LLCBought 27,021 shares on 5/4/2023Ownership: 0.269%View All Insider TransactionsView All Institutional Transactions DCTH Stock - Frequently Asked Questions Should I buy or sell Delcath Systems stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DCTH shares. View DCTH analyst ratings or view top-rated stocks. What is Delcath Systems' stock price forecast for 2023? 2 analysts have issued 1-year price targets for Delcath Systems' shares. Their DCTH share price forecasts range from $14.00 to $19.00. On average, they predict the company's stock price to reach $16.67 in the next year. This suggests a possible upside of 109.6% from the stock's current price. View analysts price targets for DCTH or view top-rated stocks among Wall Street analysts. How have DCTH shares performed in 2023? Delcath Systems' stock was trading at $3.60 at the beginning of 2023. Since then, DCTH stock has increased by 120.8% and is now trading at $7.95. View the best growth stocks for 2023 here. Are investors shorting Delcath Systems? Delcath Systems saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 457,600 shares, an increase of 7.9% from the April 30th total of 424,200 shares. Based on an average trading volume of 44,400 shares, the short-interest ratio is presently 10.3 days. View Delcath Systems' Short Interest. When is Delcath Systems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our DCTH earnings forecast. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) posted its quarterly earnings data on Monday, May, 22nd. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.20. The firm had revenue of $0.60 million for the quarter. Delcath Systems had a negative net margin of 1,212.45% and a negative trailing twelve-month return on equity of 1,396.28%. When did Delcath Systems' stock split? Delcath Systems's stock reverse split before market open on Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What guidance has Delcath Systems issued on next quarter's earnings? Delcath Systems issued an update on its first quarter 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $600.00K-$600.00K, compared to the consensus revenue estimate of $770.00K. What is Delcath Systems' stock symbol? Delcath Systems trades on the NASDAQ under the ticker symbol "DCTH." Who are Delcath Systems' major shareholders? Delcath Systems' stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.59%), Advisors Capital Management LLC (0.27%), BlackRock Inc. (0.16%), Renaissance Technologies LLC (0.11%) and Tower Research Capital LLC TRC (0.04%). Insiders that own company stock include Ernest C Garcia II, Gerard J Michel, Gil Aharon, John Purpura, Rosalind Advisors, Inc and Steven A J Salamon. View institutional ownership trends. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Delcath Systems' stock price today? One share of DCTH stock can currently be purchased for approximately $7.95. How much money does Delcath Systems make? Delcath Systems (NASDAQ:DCTH) has a market capitalization of $84.43 million and generates $2.72 million in revenue each year. The company earns $-36,510,000.00 in net income (profit) each year or ($3.73) on an earnings per share basis. How can I contact Delcath Systems? Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The official website for the company is delcath.com. The company can be reached via phone at 212-489-2100, via email at investorrelations@delcath.com, or via fax at 212-489-2102. This page (NASDAQ:DCTH) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.